Ritanserin has also been proposed for the treatment of glioblastoma by Olmez et al. who demonstrated that the mesenchymal subtype was particularly susceptible to this treatment, because DGKα inhibition resulted in the inhibition of geranylgeranyltransferase I, perturbing its downstream mediators, such as NF‐κB [217]. This evidence concerns the gene DGKA and glioblastoma.